What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Modified HGH fragment 176–191 (anti-obesity drug candidate)
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing AOD9604 inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
AOD9604 is a modified analog of the C-terminal 176-191 fragment of human growth hormone, developed at Monash University in Australia as a lipolytic / anti-obesity research and clinical-development candidate. The molecule is Tyr-hGH(177-191) — HGH residues 177-191 carrying an N-terminal tyrosine (which also supports iodination for tracking studies) — a 16-residue analog that differs from the native 176-191 fragment by a phenylalanine-to-tyrosine change at the N-terminus. AOD9604 retains the lipolytic activity associated with the HGH C-terminal region (the segment hypothesized to drive fat-cell lipolysis through a non-GH-receptor mechanism) while lacking the broader anabolic effects mediated by the full-length HGH molecule's central regions. The molecule advanced through Phase 2 clinical development for obesity but did not achieve regulatory approval; it has since transitioned to research-use and dietary-supplement markets in some jurisdictions. PeptideXpo supplies lyophilized AOD9604 at ≥99.0% HPLC purity with batch-specific COA. The N-terminal tyrosine modification distinguishes AOD9604 from the unmodified HGH Fragment 176-191, buyers should be explicit about which they want at order placement. Three standard fill sizes (2, 5, 10 mg) cover typical research and compounding workflows.
Who buys this, and why
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Documentation available on request
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Frequently asked questions
AOD9604 was developed at Monash University in Australia and advanced through Phase 2b clinical trials for obesity as a registered drug-development program. The trials produced modest weight-loss signals (smaller than what GLP-1 agonists have since demonstrated), and the program did not achieve regulatory approval as a finished drug. Following discontinuation of the obesity-drug program, AOD9604 transitioned to research-use and to dietary-supplement markets in some jurisdictions, where it is marketed under various brand names. The 'anti-obesity drug candidate' framing reflects the molecule's clinical-development history; buyers should not assume the molecule is an approved drug.
AOD9604 is derived from the C-terminal region of human GH (residues 176-191) but is not a GH receptor agonist, the GH-receptor-binding region of full-length GH is in the central portion of the protein, not the C-terminal fragment. AOD9604's lipolytic activity is hypothesized to act through a separate, non-GH-receptor mechanism. This is the key pharmacological distinction from full-length recombinant HGH: AOD9604 retains the lipolytic effects associated with the C-terminal region of GH but lacks the broader anabolic and IGF-1-stimulating effects mediated by the central GH-receptor-binding region. The downstream consequence is a substantially narrower pharmacological profile than HGH.
Related peptides
16-mer
C-terminal fragment of human growth hormone (176–191)
29-mer
GHRH 1-29 fragment
Ghrelin / GHSR pathway GH-release peptide
